

ARTICLE OPEN



Alterations in the p53 isoform ratio govern breast cancer cell fate in response to DNA damage

Luiza Steffens Reinhardt^{1,2}, Xiajie Zhang^{1,2}, Kira Groen^{1,2}, Brianna C. Morten^{1,2}, Geoffrey N. De Luliis³, Antony W. Braithwaite^{4,5}, Jean-Christophe Bourdon⁶ and Kelly A. Avery-Kiejda^{1,2}✉

© The Author(s) 2022

Our previous studies have shown that p53 isoform expression is altered in breast cancer and related to prognosis. In particular, a high $\Delta 40p53:p53\alpha$ ratio is associated with worse disease-free survival. In this manuscript, the influence of altered $\Delta 40p53$ and p53 α levels on the response to standard of care DNA-damaging agents used in breast cancer treatment was investigated in vitro. Our results revealed that a high $\Delta 40p53:p53\alpha$ ratio causes cells to respond differently to doxorubicin and cisplatin treatments. $\Delta 40p53$ overexpression significantly impairs the cells' sensitivity to doxorubicin through reducing apoptosis and DNA damage, whereas $\Delta 40p53$ knockdown has the opposite effect. Further, a high $\Delta 40p53:p53\alpha$ ratio inhibited the differential expression of several genes following doxorubicin and promoted DNA repair, impairing the cells' canonical response. Overall, our results suggest that the response of breast cancer cells to standard of care DNA-damaging therapies is dependent on the expression of p53 isoforms, which may contribute to outcomes in breast cancer.

Cell Death and Disease (2022)13:907; <https://doi.org/10.1038/s41419-022-05349-9>

INTRODUCTION

The *TP53* gene, known as the “guardian of the genome”, is one of the most commonly mutated genes in cancer, alongside the proto-oncogene *PI3KCA* [1]. Somatic mutation of the tumour suppressor gene *TP53* is related to breast cancer subtype, tumour progression, resistance to therapy, and poor prognosis in breast cancer; however, its overall mutation frequency of ~25% is less than expected for a protein that executes key functions that maintain genome integrity [2, 3].

DNA-damaging agents such as cyclophosphamide, cisplatin (CIS), and doxorubicin (DOX) are frequently used to treat breast cancer [4], but the mechanisms of resistance to these agents are poorly defined. The p53 protein is activated by a range of cellular stressors such as DNA-damaging agents, hypoxia, and nutrient starvation. This triggers multiple signalling pathways involved in the DNA damage response (DDR), including cell-cycle arrest, apoptosis, and DNA repair [5–7]. Full-length p53 (referred to herein as p53 α) is expressed at low levels and maintained in a steady state by human double minute 2 (HDM2) and its regulators p14^{ARF} and p16^{INK4A} [8–10]. Upon DNA damage, p53 α is activated through post-translational modifications (PTMs) including phosphorylation of serine residues within the transactivation domain 1 (TAD1) [9, 11]. In its active conformation, p53 α forms a tetramer and binds to p53 responsive elements (REs) in the promoter region of target genes to enhance or inhibit their expression. Interestingly, p53 α promotes some DNA repair pathways,

including the base excision repair, mismatch repair, and nucleotide excision repair pathways [12–14], while inhibiting DNA double-strand break (DSB) repair pathways, including the homologous recombination (HR), non-homologous end-joining, and single-stranded annealing pathways [11, 15–25].

Given the importance of p53 α in tumour suppression [2], and the low mutation frequency in sporadic hormone-dependent breast cancer, other mechanisms may be responsible for the disruption of this critical tumour suppressor. *TP53* is expressed as p53 α as well as 12 smaller isoforms that can modulate its function: p53 β , p53 γ , p53 ψ , $\Delta 133p53$, $\Delta 133p53\beta$, $\Delta 133p53\gamma$, $\Delta 40p53$, $\Delta 40p53\beta$, $\Delta 40p53\gamma$, $\Delta 160p53$, $\Delta 160p53\beta$, and $\Delta 160p53\gamma$ [26–28]. Studies indicate that the isoforms can enhance or inhibit the ability of p53 α to transactivate certain target genes and to induce apoptosis [5, 26, 29–31], senescence [31–34], and angiogenesis [32, 35, 36]. The p53 isoforms can be generated through alternative splicing ($\Delta 40$, β , γ), alternative promoter usage ($\Delta 133$, $\Delta 160$), and alternative initiation of translation ($\Delta 40$, $\Delta 160$) [26, 27]. All N-terminal isoforms lack the HDM2 binding domain and this is thought to contribute to their increased stability [37].

Our previous studies have shown that $\Delta 40p53$ is the most highly expressed p53 isoform in breast cancer, aside from p53 α itself, with significantly higher expression in tumour samples compared to matched normal adjacent tissue [38]. Additionally, a high $\Delta 40p53:p53\alpha$ ratio is associated with increased likelihood of metastasis and recurrence, suggesting that this isoform plays a

¹School of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellbeing, The University of Newcastle, Callaghan, NSW, Australia. ²Hunter Medical Research Institute, New Lambton Heights, NSW, Australia. ³Priority Research Centre for Reproductive Science, School of Environmental and Life Sciences, College of Engineering, Science and Environment, The University of Newcastle, Callaghan, NSW, Australia. ⁴Children's Medical Research Institute, The University of Sydney, Sydney, NSW, Australia. ⁵Department of Pathology, School of Medicine, The University of Otago, Dunedin, New Zealand. ⁶Dundee Cancer Centre, Ninewells Hospital and Medical School, The University of Dundee, Dundee, UK. ✉email: Kelly.kiejda@newcastle.edu.au

Edited by Professor Gerry Melino

Received: 23 March 2022 Revised: 13 October 2022 Accepted: 14 October 2022

Published online: 28 October 2022

role in breast cancer carcinogenesis and that it may alter therapeutic outcomes [38, 39].

$\Delta 40p53$ is known to play a key role in the response to endoplasmic reticulum stress [33], however, little is known about the underlying mechanisms by which $\Delta 40p53$ orchestrates an altered p53 response to DNA damage, especially in regard to p53 pathways important in carcinogenesis, such as DNA repair and apoptosis. Most chemotherapies used to treat breast cancer work by inflicting DNA-damage to drive cancer cells towards apoptosis. Therefore, defining the role of $\Delta 40p53$ in the p53-mediated DDR may uncover novel chemoresistance mechanisms. In this study, the role of $\Delta 40p53$ in the p53-mediated DDR to DOX and CIS was investigated. Our data show that altered levels of $\Delta 40p53$ modulate cell fate in a drug-dependent fashion and that $\Delta 40p53$ is involved in modulating the p53-mediated DDR by promoting DNA repair and antagonising apoptosis, in response to chemotherapy-driven DNA-damage, which may result in decreased sensitivity to these therapies.

RESULTS

p53 α and $\Delta 40p53$ are highly expressed in response to DNA damage

To determine if $\Delta 40p53$ levels could be modulated by DNA-damaging chemotherapies, $\Delta 40p53$ expression was analysed following 24 h treatment with DOX or CIS. For this analysis, two breast cancer cell lines that harbour WTp53 were used, MCF-7 and ZR75-1. Following treatment, protein was extracted from cell pellets or cells were fixed for immunofluorescence of p53 α and $\Delta 40p53$. At the basal level, in MCF-7 cells, approximately 22% and 6% of cells stained for p53 α and $\Delta 40p53$, respectively, whereas, in ZR75-1 cells, approximately 12% and 4% of cells stained for p53 α and $\Delta 40p53$, respectively (Fig. 1A). In both cell lines, p53 α (Fig. 1B, D, F) and $\Delta 40p53$ (Fig. 1B, C, E, G) were highly expressed after DOX or CIS treatment (Fig. 1B–D). In the absence of treatment, endogenously expressed $\Delta 40p53$ was localised predominantly in the cytoplasm, confirming previous *in vitro* studies overexpressing this isoform [40, 41] (Fig. 1H). However, after DOX treatment, $\Delta 40p53$'s nuclear expression increased by 2-fold in MCF-7 cells (Fig. 1I) and by more than 2.5-fold in ZR75-1 cells (Fig. 1J).

Knockdown of $\Delta 40p53$ alters cell cycle progression after doxorubicin treatment

Having demonstrated that $\Delta 40p53$ is induced by genotoxic agents, we next explored the function of $\Delta 40p53$ in the DDR by using breast cancer cell lines in which $\Delta 40p53$ has been stably knocked down (sh $\Delta 40p53$) or overexpressed ($\Delta 40p53$) [42]. To compare these results with the function of p53 α , a TAp53 knockdown subline was used along with sublines containing a non-targeting control shRNA (shNT) or empty vector (LeGO) [42]. The response of these sublines to DOX and CIS was examined by cell cycle analysis.

Knockdown of $\Delta 40p53$ in MCF-7 cells led to a significant increase in the G1 population ($p = 0.002$) and a decrease in the S ($p = 0.0011$) and G2 populations ($p = 0.00018$) after DOX treatment compared to shNT cells (Fig. 2A–D), whereas in the ZR75-1 cells, $\Delta 40p53$ -knockdown had limited impact on G1 phase but led to a significantly reduced induction of G2 in response to either drug (DOX-treated cells: $p = 0.048$; CIS-treated cells: $p = 0.002$), when compared to shNT transduced cells (Supplementary Fig. 2A–F). Knockdown of p53 α significantly reduced the number of cells in G1 and increased the proportion of cells in G2 in both MCF-7 and ZR75-1 cells following CIS or DOX treatment compared to shNT cells ($p < 0.05$ for all comparisons, except G2 of CIS-treated ZR75-1-shp53 α vs. shNT, see Figure for details; Fig. 2A–D, I–L, Supplementary Fig. 2A–F), and sh $\Delta 40p53$ cells ($p < 0.05$ for all comparisons, Fig. 2A–D, I–L, Supplementary Fig. 2A–F). In the same manner, the MCF-7- $\Delta 40p53$ subline exhibited a significant

reduction in the proportion of cells in G1 ($p = 0.0132$) and a significant increase in the proportion of cells in G2 ($p = 0.0102$) in response to DOX when compared to MCF-7-LeGO cells (Fig. 2E–H). However, the MCF-7- $\Delta 40p53$ subline had a lower proportion of cells in G2 in response to CIS when compared to vehicle-treated cells ($p = 0.0096$) (Fig. 2M, P).

Overall, DOX led to more pronounced cell cycle changes when compared to CIS, with a high $\Delta 40p53$:p53 α ratio ($\Delta 40p53$ -overexpression or p53 α -knockdown) [42] reducing the number of cells in G1 and enhancing the proportion of cells in G2 following DOX; while the opposite was observed in cells with a low $\Delta 40p53$:p53 α ratio ($\Delta 40p53$ -knockdown) (Fig. 2, Supplementary Fig. 2A–C).


Knockdown of $\Delta 40p53$ enhances apoptosis after doxorubicin treatment

DNA damage can trigger cell cycle arrest, leading to DNA repair, or cell death. Our results have shown that the $\Delta 40p53$:p53 α ratio can alter cell cycle progression at specific phases depending on the DNA-damaging agent, but whether the cells repaired the damaged DNA and continued to survive or underwent apoptosis remains unknown. Therefore, we investigated whether an alteration in $\Delta 40p53$ or p53 α expression affected apoptosis induced by DOX or CIS.

In MCF-7 sublines, $\Delta 40p53$ knockdown increased the rate of apoptosis and $\Delta 40p53$ overexpression attenuated apoptosis in response to DOX (Fig. 3A, B). Knockdown of p53 α had limited effects on the apoptosis rate when compared to shNT cells (Fig. 3A). The MCF-7- $\Delta 40p53$ subline exhibited a decreased apoptosis rate compared to LeGO cells when treated with CIS, however, there were no differences in the apoptosis rate in the knockdown sublines (Fig. 3C, D). In ZR75-1 sublines, knockdown of $\Delta 40p53$ resulted in a significant reduction in DOX-induced cell viability after 96 h of treatment ($p = 0.0363$) and apoptosis after 72 h of treatment ($p < 0.0001$), whereas the subline in which p53 α was knocked down demonstrated less sensitivity to the treatment (Supplementary Fig. 2G, H), but no differences were found in CIS-treated cells (Supplementary Fig. 2I). These results show that in response to two DNA-damaging agents, high $\Delta 40p53$ levels inhibited apoptosis.

Next, we investigated p53-dependent cell cycle and apoptosis-related gene expression by RT-qPCR. We looked at the relative mRNA expression changes of four commonly known p53-dependent target genes including *CDKN1A* (p21) and three pro-apoptotic markers *BAX*, *PUMA*, and *NOXA* (Fig. 3E–T, Supplementary Fig. 2J–L). In the MCF-7 cells, all genes were upregulated 24 h after treatment with either DNA-damaging agent. The expression level of all three pro-apoptotic genes was significantly upregulated ($p < 0.05$) when $\Delta 40p53$ was knocked down and significantly downregulated ($p < 0.05$) when p53 α was knocked down (Fig. 3E–G, I–K). The expression of *CDKN1A* was not significantly different among the knockdown MCF-7 sublines in response to DOX or CIS treatment (Fig. 3H, L). This supports our results that $\Delta 40p53$ knockdown led to increased apoptosis. In contrast, the induction of *BAX*, *NOXA*, *PUMA*, and *CDKN1A* expression was inhibited in MCF-7- $\Delta 40p53$ cells following DOX treatment (Fig. 3M–P). However, $\Delta 40p53$ overexpression had no effect on CIS-mediated induction of these genes (Fig. 3Q–T). In ZR75-1 sublines, no statistically significant differences were observed in the expression of *BAX*, *PUMA*, and *NOXA* after DOX treatment (Supplementary Fig. 2J–L).

To confirm the differential sensitivity to DOX among the cell sublines, cell spheroids were generated and their size and viability were evaluated (Fig. 3U–Y, Supplementary Fig. 2M, N). $\Delta 40p53$ knockdown decreased spheroid size and viability following treatment in both MCF-7 and ZR75-1 cells (Fig. 3U, V, Supplementary Fig. 2M, N), whereas, MCF-7- $\Delta 40p53$ spheroids showed less sensitivity to DOX when compared to LeGO spheroids (Fig. 3W, X).



These results suggest that varying Δ 40p53:p53 α ratios promote different cellular decisions by modulating the transactivation of p53 α -target genes in a DNA damaging agent-specific fashion, resulting in differential apoptosis rates and sensitivity to DOX.

p53 α is upregulated by Δ 40p53 knockdown after doxorubicin treatment

The above results show that Δ 40p53 knockdown significantly increased apoptosis and pro-apoptotic gene expression; thus, we hypothesised that endogenously expressed Δ 40p53 may alter

Fig. 1 p53 α and Δ 40p53 are highly expressed in response to DNA damage in MCF-7 and ZR75-1 cell lines. **A** The percentage of cells positive for p53 α and Δ 40p53 at the basal level in MCF-7 and ZR75-1 cells analysed by immunofluorescence using DO-1 (1:100) and KJC40 (1:70) primary antibodies. The corresponding average percentage is shown at the top of the columns. Data shown represent three independent experiments of three technical replicates. **B** Representative immunoblotting analysis of MCF-7 and ZR75-1 cell extracts (40 μ g) treated with vehicle (water), DOX or CIS (24 h). CM-1 (1 μ g/ml) and GAPDH (1 μ g/ml; loading control) primary antibodies were used. Data shown represent three independent experiments. Fold-change expression relative to vehicle-treated cells for MCF-7 cell extracts: p53 α 20.9-fold (DOX) and 5.5-fold (CIS), Δ 40p53 43.6-fold (DOX) and 13.3-fold (CIS); and for ZR75-1 cell extracts: p53 α 8.9-fold (DOX) and 7.7-fold (CIS), Δ 40p53 9-fold (DOX) and 3-fold (CIS). **C** Immunofluorescence images of p53 α and Δ 40p53 staining before and after treatment with vehicle (water), DOX or CIS (24 h) in MCF-7 and ZR75-1 cell lines. DO-1 (1:100) and KJC40 (1:70) primary antibodies were used and cell nuclei were stained with DAPI. Data shown represent three independent experiments. For negative controls of primary and secondary antibodies see Supplementary Fig. 1. **D** p53 α and **E** Δ 40p53 expression in relative fluorescence units (RFU) normalised to cell count after DOX or CIS treatment (24 h) in the MCF-7 cell line. Data shown represent three independent experiments of three technical replicates. **F** p53 α and **G** Δ 40p53 expression after DOX or CIS treatment (24 h) in the ZR75-1 cell line. Data shown represent three independent experiments of three technical replicates. **H** The nuclear/cytoplasmic ratio expression of Δ 40p53 after treatment with vehicle or DOX (24 h) in MCF-7 cells and **I** ZR75-1 cells. Data shown represent three independent experiments of three technical replicates. **J** Immunofluorescence images of Δ 40p53 staining after treatment with vehicle or DOX (24 h) in ZR75-1 cells. KJC40 (1:70) primary antibody was used and cell nuclei are stained with DAPI. Results are shown as the mean \pm SD. Statistical analyses were carried out using one-way ANOVA followed by Dunnett's post-test (**D–G**) or unpaired *t*-test (**H, I**). Results were considered significant at $p < 0.05$; ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$.

p53 α expression and activation following DNA damage. To investigate this, p53 α protein expression was examined. There was a time-dependent increase in p53 α expression in all MCF-7 sublines when treated with either drug, except for cells overexpressing Δ 40p53 (MCF-7- Δ 40p53 cells; Fig. 4A). In MCF-7- Δ 40p53 cells, elevated p53 α was observed at the basal level and its expression at the protein level did not change following DNA-damage (Fig. 4A).

Induction of p53 α protein expression following DNA damage in sh Δ 40p53 cells was significantly enhanced compared to shNT cells (Fig. 4A), which may explain increased apoptosis in these cells. p53 α was moderately induced by CIS and DOX in shp53 α cells, however it was significantly reduced when compared to shNT cells (Fig. 4A). To confirm p53 α protein expression, immunofluorescence was performed for the full-length protein and its phosphorylated form (phosphorylation site: Ser¹⁵ residue) (Fig. 4B–D). In both cell lines, knockdown of Δ 40p53 upregulated the nuclear expression of p53 α and its phosphorylated form (Fig. 4B–D), whereas the overexpression of Δ 40p53 stabilised p53 α levels but did not alter phosphorylation.

The apparent higher stability of p53 α in the MCF-7- Δ 40p53 subline was further analysed and cells were treated with the translation inhibitor, CHX and/or the proteasome inhibitor, MG132 (Fig. 4E, F). As expected, the levels of p53 α decreased in a time-dependent manner following translation inhibition with CHX in LeGO and Δ 40p53 cells, however, the extent of reduction in Δ 40p53 cells was much less than that observed in the LeGO subline, indicating an increased half-life of p53 α when Δ 40p53 is overexpressed (Fig. 4E, F).

The effect of translation inhibition on p53 α levels was partially attenuated by the addition of MG132 in LeGO cells. In contrast, in Δ 40p53 cells, p53 α expression remained unaffected by MG132 treatment, supporting previous studies that Δ 40p53 overexpression increases p53 α 's protein half-life due to modulation of p53 α proteasomal degradation [43, 44] (Fig. 4E, F). It should be noted that even though the levels of p53 α were increased in the Δ 40p53 subline, the expression of Δ 40p53 was still comparatively higher (7-fold) than that of p53 α (Fig. 4E). As expected, in Δ 40p53 cells, Δ 40p53 expression was not affected by either treatment (Fig. 4E), supporting previous studies that demonstrated that this isoform exhibits an increased half-life when compared to the full-length protein [5, 30, 37, 43].

p53 α and Δ 40p53 co-occur and co-localise after doxorubicin treatment

Δ 40p53 retains the oligomerisation domain (OD) and when ectopically expressed, can form hetero-complexes with p53 α [5, 26, 28, 33, 45] that can modify p53 α -target gene expression. To determine if the endogenously expressed proteins are capable of

interacting, the co-occurrence (presence of the two proteins in the same cell), co-localisation (correlation analysis), and proximity ligation assays (PLA) of Δ 40p53/p53 α complexes before and after DOX treatment was analysed in MCF-7 and ZR75-1 cells. A distinct endogenous expression pattern was observed for each of the isoforms: while p53 α was predominantly nuclear, Δ 40p53 was expressed as punctate aggregates within the cell, mainly in the cytoplasm (Fig. 5A).

Co-occurrence: At the basal level (in the absence of DOX), 6.3% of MCF-7 cells or 3.2% of ZR75-1 cells highly expressed both p53 α and Δ 40p53, whereas the majority of cells did not express either protein or p53 α and Δ 40p53 were expressed alone in individual cells (Fig. 5B). Nevertheless, the number of cells highly expressing both proteins increased around 5-fold following DOX treatment (Fig. 5B).

Co-localisation: The co-localisation of p53 α and Δ 40p53 was not detected in vehicle-treated cells, where p53 α was predominantly localised in the nucleus and Δ 40p53 in the cytoplasm. In contrast, following DOX treatment the expression of Δ 40p53 became more nuclear (Fig. 5A) and there was a dramatic increase in the co-localisation of p53 α and Δ 40p53 in both cell lines (Fig. 5A, C).

The physical interaction between these isoforms following DOX treatment was confirmed by co-immunoprecipitation (Fig. 5D, upper panel, lane 3; Supplementary Fig. 3) and PLA (Fig. 5E, F). In vehicle-treated MCF-7 and ZR75-1 cells, an interaction between Δ 40p53 and p53 α was detected, however, PLA intensity and the number of PLA puncta per cell significantly increased following treatment ($p < 0.05$) (Fig. 5F). These results confirm the endogenous formation of Δ 40p53/p53 α complexes and the enhancement of this complex formation following DOX treatment.

In order to compare the stability of different compositions of Δ 40p53/p53 α tetramers, *in silico* molecular modelling was used, calculating the minimisation potential energies of homo- and hetero-complexes bound to the DNA (Fig. 5G). The p53 α homo-complex presented the lowest calculated potential energy (−91674.7 kcal/mol; not shown, this value was set as zero with the relative potential energy of subsequent tetramer configurations reported), suggesting a more favourable assembly and/or higher stability. Although the Δ 40p53 homo-complex exhibits structural similarities to p53 α at the immediate DNA binding interface, the loss of TAD1 in the Δ 40p53 isoform alters the interacting surfaces between the protein subunits, which may impact tetramer formation. The calculated potential energy for the assembled Δ 40p53 homo-complex was considerably higher (+7287.8 kcal/mol) than the p53 α tetramer (0 kcal/mol), suggesting the formation of a Δ 40p53 complex may be less favourable (Supplementary Fig. 4). The calculated potential energies for the hetero-complexes yielded values between the two homo-complexes with higher energies computed for each complex




Fig. 2 Modulation of $\Delta 40p53$ levels alters cell cycle progression in response to DNA damage. **A** Representative histograms of DOX-treated (24 h) MCF-7-shNT (shown in black), MCF-7-sh $\Delta 40p53$ (shown in blue) and MCF-7-shp53 α (shown in pink) sublines. Relative change in **B** G1-phase, **C** S-phase and **D** G2-phase in MCF-7-shNT, MCF-7-sh $\Delta 40p53$ and MCF-7-shp53 α sublines. **E** Representative histograms of DOX-treated (24 h) MCF-7-LeGO (shown in black) and MCF-7- $\Delta 40p53$ (shown in orange) sublines. Relative change in **F** G1-phase, **G** S-phase and **H** G2-phase in MCF-7-LeGO and MCF-7- $\Delta 40p53$ sublines. **I** Representative histograms of CIS-treated (24 h) MCF-7-shNT (shown in black), MCF-7-sh $\Delta 40p53$ (shown in blue) and MCF-7-shp53 α (shown in pink) sublines. Relative change in **J** G1-phase, **K** S-phase and **L** G2-phase in MCF-7-shNT, MCF-7-sh $\Delta 40p53$ and MCF-7-shp53 α sublines. **M** Representative histograms of CIS-treated (24 h) MCF-7-LeGO (shown in black) and MCF-7- $\Delta 40p53$ (shown in orange) sublines. Relative change in **N** G1-phase, **O** S-phase and **P** G2-phase in MCF-7-LeGO and MCF-7- $\Delta 40p53$ sublines. Data shown represent three independent experiments of three technical replicates. Results are shown as the mean \pm SD. Statistical analyses were carried out using an unpaired t-test. Results were considered significant at $p < 0.05$.


containing an additional $\Delta 40p53$ subunit (Fig. 5G). This indicates that the presence of the $\Delta 40p53$ isoform may diminish total stability, when incorporated in the p53 complex (Fig. 5G; Supplementary Fig. 4).

Knockdown of $\Delta 40p53$ increases DNA damage at early time points following DOX treatment

Given our previous results showing decreased apoptosis induction following DOX in cells expressing high levels of $\Delta 40p53$, we next determined if this isoform could impair the DOX-induced DDR. The mechanisms of DOX-mediated cell death are generation of reactive oxygen species, formation of DNA adducts and entrapment of topoisomerase II (TOPOII), which increases torsional strain and causes DSB [46]. Thus, DSBs were evaluated by the formation

of γ H2AX foci at the break sites after DOX treatment at different time points. Both sh $\Delta 40p53$ sublines demonstrated increased DNA damage as judged by γ H2AX staining when compared to the shNT sublines after 3 and 6 h of treatment (Fig. 6A). In contrast, the overexpression of $\Delta 40p53$ was associated with significantly decreased DNA damage after 3 h ($p = 0.0180$) (Fig. 6A), indicating that $\Delta 40p53$ may impair the DDR after DOX exposure. The results were confirmed by comet assays in MCF-7 sublines, where sh $\Delta 40p53$ exhibited the highest tail moment value compared to shNT and shp53 α sublines after 6 h of DOX treatment (Supplementary Fig. 5).

p53 can modulate DNA repair pathways via direct interactions with proteins such as RAD51 and BRCA1 [11, 15]. Since we observed increased DSB formation/signalling when $\Delta 40p53$ was



knocked down and decreased DNA damage when this isoform was overexpressed, we investigated DSB repair by analysing BRCA1 and RAD51 expression. Increased BRCA1 and RAD51 expression were observed in ZR75-1 and MCF-7 shp53α sublines following DOX treatment (Fig. 6B, C), confirming the regulatory effect of p53α on these proteins. Significantly increased

expression of BRCA1 ($p=0.0077$) and RAD51 ($p=0.0018$) was also observed in MCF-7-Δ40p53 cells after treatment when compared to the LeGO subline (Fig. 6B, C). In contrast, knockdown of Δ40p53 had no significant effect on the expression of RAD51 or BRCA1 (Fig. 6B, C). After 3 h of DOX treatment, p53α was shown to co-localise with BRCA1 (Supplementary Fig. 6A, B) and RAD51

Fig. 3 Knockdown of $\Delta 40p53$ enhances apoptosis after DOX treatment, whereas $\Delta 40p53$ overexpression decreases apoptosis following DOX or CIS treatment. Annexin-V positive cells normalised to confluence in **A** MCF-7-shNT, MCF-7-sh $\Delta 40p53$ and MCF-7-shp53 α sublines and **B** MCF-7-LeGO and MCF-7- $\Delta 40p53$ sublines following DOX treatment. Data shown represent four independent experiments of three technical replicates. Annexin-V positive cells normalised to confluence in **C** MCF-7-shNT, MCF-7-sh $\Delta 40p53$ and MCF-7-shp53 α sublines and **D** MCF-7-LeGO and MCF-7- $\Delta 40p53$ sublines following CIS treatment. Data shown represent four independent experiments of three technical replicates. mRNA levels of **E** *BAX*, **F** *NOXA*, **G** *PUMA* and **H** *CDKN1A* in response to DOX normalised to vehicle-treated cells in MCF-7-shNT, MCF-7-sh $\Delta 40p53$ and MCF-7-shp53 α sublines. Data shown represent three independent experiments of three technical replicates. mRNA levels of **I** *BAX*, **J** *NOXA*, **K** *PUMA* and **L** *CDKN1A* in response to CIS normalised to vehicle-treated cells in MCF-7-shNT, MCF-7-sh $\Delta 40p53$ and MCF-7-shp53 α sublines. Data shown represent three independent experiments of three technical replicates. mRNA levels of **M** *BAX*, **N** *NOXA*, **O** *PUMA* and **P** *CDKN1A* in response to DOX normalised to vehicle-treated cells in MCF-7-LeGO and MCF-7- $\Delta 40p53$ sublines. Data shown represent three independent experiments of three technical replicates. mRNA levels of **Q** *BAX*, **R** *NOXA*, **S** *PUMA* and **T** *CDKN1A* in response to CIS normalised to vehicle-treated cells in MCF-7-LeGO and MCF-7- $\Delta 40p53$ sublines. Data shown represent three independent experiments of three technical replicates. **U** Spheroid size normalised to size prior treatment with DOX and **V** spheroid viability normalised to vehicle-treated spheroids in MCF-7-shNT, MCF-7-sh $\Delta 40p53$ and MCF-7-shp53 α sublines. **W** Spheroid size normalised to size prior to treatment with DOX and **X** spheroid viability normalised to vehicle-treated spheroids in MCF-7-LeGO and MCF-7- $\Delta 40p53$ sublines. Data shown represent three independent experiments of four technical replicates. **Y** Representative images of vehicle or DOX-treated MCF-7 sublines spheroids on day 0 (prior treatment) and day 14. Results are shown as the mean \pm SD. Statistical analyses were carried out using two-way ANOVA followed by Sidak's post-test (**A–U**, **W**), using one-way ANOVA followed by Tukey's post-test **V** or unpaired *t*-test **X**. Results were considered significant at $p < 0.05$; * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$.

(Supplementary Fig. 6C, D) in MCF-7 and ZR75-1 parental cells, whereas $\Delta 40p53$ did not co-localise significantly with either protein. These results were supported by PLA, where it was possible to detect cells where either $\Delta 40p53$ or p53 α interacted with BRCA1 or RAD51, however, following DOX, only p53 α 's interaction with BRCA1 and RAD51 increased (Supplementary Fig. 6E, F).

Molecular characterisation of the role of $\Delta 40p53$ in the cellular response to doxorubicin

To further characterise the mechanisms driving altered DOX responses in cells expressing modified levels of $\Delta 40p53$, sublines were treated with DOX for 24 h and their transcriptome was sequenced. Transcript expression was compared between treated sublines expressing high (MCF-7- $\Delta 40p53$) and endogenous (MCF-7-LeGO) levels of $\Delta 40p53$; and between treated sublines expressing low levels (sh $\Delta 40p53$ and shp53 α) and endogenous (shNT) levels of either $\Delta 40p53$ or p53 α . Additional comparisons were made between the molecular profiles of treated and untreated cells of each subline to determine whether differential gene expression was already present at the basal level or the result of enhanced/inhibited expression of a particular gene in response to DOX. Using these comparisons, drivers of differential expression were classified in instances where statistical significance was reached (for detailed information regarding the comparisons that were performed and the genes that were differentially expressed, please refer to Supplementary Tables S2–S6 and Supplementary text). In this analysis, 7,390 genes passed quality control and were included.

MCF-7- $\Delta 40p53$. RNA-seq revealed 95 differentially expressed genes (DEGs) between DOX-treated $\Delta 40p53$ and LeGO cells (1.3%, 95/7390). Differential expression of these genes was driven by the inhibition of DOX-mediated downregulation in $\Delta 40p53$ cells (Fig. 7A, cluster 1), the inhibition of DOX-mediated upregulation in $\Delta 40p53$ cells (Fig. 7A, cluster 2), or increased expression at baseline that was maintained throughout DOX treatment in $\Delta 40p53$ cells (Fig. 7A, cluster 3).

MCF-7-sh $\Delta 40p53$ and MCF-7-shp53 α . Two hundred and thirty-six genes (3.2%, 236/7390) were differentially expressed between DOX-treated sh $\Delta 40p53$ and shNT cells (Fig. 7B, Supplementary Table S3). Knockdown of $\Delta 40p53$ inhibited the downregulation of 22 genes (Fig. 7B, cluster 4) and the upregulation of 57 genes (Fig. 7B, cluster 2). p53 α knockdown only resulted in 97 DEGs (1.3%, 97/7390), compared to DOX-treated shNT cells (Fig. 7B, Supplementary Table S4). p53 α knockdown inhibited the upregulation of 41 genes (Fig. 7B, cluster 1) and the downregulation of 14 genes (Fig. 7B, cluster 3) compared to shNT cells and this inhibition was not evident in sh $\Delta 40p53$ cells.

ZR75-1-sh $\Delta 40p53$ and ZR75-1-shp53 α . In ZR75-1 sublines, 124 genes (1.7%, 124/7930) were differentially expressed between DOX-treated sh $\Delta 40p53$ and shNT cells (Fig. 7C, Supplementary Table S5). Forty-one downregulated genes already exhibited decreased expression in sh $\Delta 40p53$ cells at baseline and this was maintained following DOX treatment (Fig. 7C, cluster 4), whereas 19 genes were already upregulated at baseline (Fig. 7C, cluster 3). p53 α knockdown resulted in 139 DEGs (1.7%, 139/7930), compared to DOX-treated shNT cells (Fig. 7C, Supplementary Table S6). Compared to $\Delta 40p53$ knockdown, p53 α knockdown did not affect genes in cluster 3 (Fig. 7C) but inhibited the downregulation of 36 genes (Fig. 7C, cluster 2), and downregulated 11 genes already at baseline (Fig. 7C, cluster 1).

Overlap between the MCF-7 and ZR-75-1 sublines and functional annotations. Twenty-eight DEGs in MCF-7- $\Delta 40p53$ cells, showed the opposite regulation in MCF-7-sh $\Delta 40p53$ cells (Fig. 7D). Additionally, there was little overlap between MCF-7 and ZR75-1 knockdown sublines (Fig. 7E), suggesting that different mechanisms govern the altered responses to DOX in each of these sublines (Supplementary Table S7, 8). Functional annotations of the DEGs that are linked to DOX sensitivity in the MCF-7 sublines showed that increased levels of $\Delta 40p53$ or decreased levels of p53 α (i.e. MCF-7- $\Delta 40p53$ vs MCF-7-LeGO, MCF-7-shNT vs MCF-7-sh $\Delta 40p53$, and MCF-7-shNT vs MCF-7-shp53 α) upregulate genes linked to DNA repair, inhibition of apoptosis, proliferation, and worse prognosis (yellow fields); and downregulate genes related to apoptosis, inhibition of proliferation, and better prognosis following DOX treatment (blue fields) (Fig. 7F).

The investigation of each of the individual genes' function highlighted some important themes. The upregulation of genes linked to the inhibition of apoptosis (e.g. *MELK*, *NDC80*, *UHRF1*; confirmed by RT-qPCR, Fig. 8A–C), DNA repair (e.g. *TRIP13*, confirmed by RT-qPCR, Fig. 8D), proliferation, and worse prognosis/chemoresistance (*PDK3* [47], *DDB1*, [48], *USP47* [49], *CDT1* [50]) in DOX-treated MCF-7- $\Delta 40p53$ cells compared to MCF-7-LeGO cells and in MCF-7-shNT cells compared to MCF-7-sh $\Delta 40p53$ cells; were common events linked to the alteration of $\Delta 40p53$ expression. In confirmation, genes involved in apoptosis, inhibition of proliferation, and better prognosis (*SLIT1* [51], *PTPN4* [52], *TPM2* [53], *CAPNS1* [54]) were downregulated (Fig. 7F), supporting data from functional assays (Fig. 3).

To further evaluate the impact of DEGs in MCF-7 sublines on p53 pathway activity, which is typically activated during the DDR [55], interactions between differentially expressed genes and key p53 pathway proteins were assessed through STRING [56]. Several DEGs detected by RNA-seq were found to interact with key p53 pathway proteins (Fig. 8E, Supplementary Table S9). The expression of these





Fig. 4 $\Delta 40p53$ knockdown increases the expression and phosphorylation of p53 following DOX treatment. **A** Representative immunoblotting analysis from 40 μ g of protein extracts showed that p53 protein levels were upregulated after CIS and DOX treatment (**C**, **D** represent CIS and DOX respectively and digits indicate time (hours) after treatment) in the MCF-7-shNT, MCF-7-sh $\Delta 40p53$, MCF-7-shp53 α and MCF-7-LeGO sublines, but not in the MCF-7- $\Delta 40p53$ subline. Fold-change expression is indicated by the digits between p53 and GAPDH western blots. CM-1 (1 μ g/ml) and GAPDH (1 μ g/ml; loading control) primary antibodies were used. Data shown represent three independent experiments. **B** p53 α nucleus/cytoplasmic ratio and **C** P-p53 (S15) expression measured by immunofluorescence after DOX treatment (24 h) in MCF-7 (-shNT, -sh $\Delta 40p53$, -shp53 α , LeGO and $\Delta 40p53$) and ZR75-1 (-shNT, -sh $\Delta 40p53$, -shp53 α) sublines. Data shown represent three independent experiments of three technical replicates. **D** Immunofluorescence images of p53 α staining after treatment with vehicle (water) or DOX (24 h) in MCF-7 (-shNT, -sh $\Delta 40p53$, -shp53 α , LeGO and $\Delta 40p53$) sublines. DO-1 (1:100) and P-p53 (S15) (1:400) primary antibodies were used and cell nuclei were stained with DAPI. **E** Representative immunoblotting analysis of MCF-7-LeGO and MCF-7- $\Delta 40p53$ cell extracts treated with vehicle (water), CHX (40 μ M), MG132 (10 μ M) and/or DOX (1 μ M). CM-1 (1 μ g/ml) and GAPDH (1 μ g/ml) primary antibodies were used. Data shown represent three independent experiments. **F** Quantification of p53 α expression of MCF-7-LeGO and MCF-7- $\Delta 40p53$ cell extracts treated with vehicle (water), CHX (40 μ g/ml), MG132 (10 μ M) and/or DOX (1 μ M). Data shown represent three independent experiments. Results are shown as the mean \pm SD. Statistical analyses were carried out using two-way ANOVA followed by Sidak's post-test. Results were considered significant at $p < 0.05$; * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$.

upstream and downstream p53 interactions associated with DOX-related DDR (*ATM*, *ATR*, *CHEK2*, *HDM2*, *MAPK1*, *EP300*, *TOPOII α* , *TOPOII β* , *BRCA1*, *RAD51*, *RAD52*, *LIG4*, *PARP1*, *APEX1*, *OGG1*) was analysed by RT-qPCR in MCF-7 sublines after 6 and 24 h of DOX treatment and compared to untreated cells (Fig. 8F). p53 α knockdown induced the upregulation of *TOPOII α* , *BRCA1*, and

PARP1 following 24 h of treatment when compared to shNT and sh $\Delta 40p53$ cells (Fig. 8F, Supplementary Fig. 7G, I, M), which may indicate higher activation of DNA repair after treatment. In contrast, no statistically significant differences were found in MCF-7-sh $\Delta 40p53$ cells (Fig. 8F, Supplementary Fig. 7) when compared to shNT cells.



However, when Δ40p53 was overexpressed a significant increase in *RAD51* expression (Fig. 8F, Supplementary Fig. 8J) was observed, corroborating the protein expression results (Fig. 6B, C) and indicating a specific upregulation of the HR DSB repair pathway in these cells.

DISCUSSION

The tumour suppressor p53α plays a critical role in maintaining DNA integrity and guiding cellular responses to stress stimuli [57]. We have uncovered novel mechanisms of p53 signalling disruption by Δ40p53 in breast cancer cells following DNA damaging

Fig. 5 p53 and $\Delta 40p53$ co-occur and co-localise after treatment with DOX. **A** Immunofluorescence images of p53 α and $\Delta 40p53$ staining after treatment with vehicle (water) or DOX (24 h) in the ZR75-1 cell line. DO-1 (1:100) and KJC40 (1:70) primary antibodies were used and cell nuclei were stained with DAPI. **B** Co-occurrence of p53 and $\Delta 40p53$ (the presence of both isoforms in the same cell) after treatment with vehicle or DOX in the MCF-7 and ZR75-1 parental cell lines. DO-1 (1:100) and KJC40 (1:70) primary antibodies were used. The mean fluorescence of each stain was used as a threshold and cells with higher or equal fluorescence were considered positive. Data shown represent three independent experiments of three technical replicates. **C** Co-localisation of p53 and $\Delta 40p53$ after treatment with vehicle or DOX in the MCF-7 and ZR75-1 parental cell lines. DO-1 (1:100) and KJC40 (1:70) primary antibodies were used. Data shown represent three independent experiments. Spearman's rank correlation was used for the co-localisation analyses. **D** Co-immunoprecipitation of p53 and $\Delta 40p53$ from 500 μ g protein extract (from DOX-treated MCF-7- $\Delta 40p53$ cells) using 1 μ g of anti-p53 α (DO-1). Upper panel: the blot was probed for $\Delta 40p53$ (KJC40 antibody; 2.5 μ g/mL); lower panel: the blot was probed for p53 (7F5 antibody; 1 μ g/mL). For whole membrane, see Supplementary Fig. 3. **E** Representative images of proximity ligation assay (PLA) detection of p53 and $\Delta 40p53$ interaction in MCF-7 and ZR75-1 treated with vehicle or DOX. PLA is visualised as red puncta and cell nuclei were stained with DAPI. **F** PLA quantification in MCF-7 and ZR75-1 cells treated with vehicle or DOX. Results are shown as relative fluorescence units (RFU) (left) and the number of PLA puncta per cell count (right). Data shown represent three independent experiments. Results are shown as the mean \pm SD. Statistical analyses were carried out using an unpaired *t*-test. Results were considered significant at $p < 0.05$. **G** In silico minimisation potential energy of p53 α and $\Delta 40p53$ hetero-complexes with DNA. p53 α is shown in blue and $\Delta 40p53$ in grey. Transactivation domain I (TAD1) is shown in magenta (residues 1–40) and transactivation domain II (TADII) is shown in orange (residues 41–61). Each tetramer/DNA complex was energy minimised (CHARMM) with the resultant potential energy (kcal/mol) normalised by the complex with the lowest energy (p53 α homo-complex). For sequence alignment and minimisation potential energy calculations of all tetramers see Supplementary Fig. 4.

treatment. In this study, overexpression and molecular inhibition were used to modulate the $\Delta 40p53$:p53 α ratio and investigate the influence of altered $\Delta 40p53$ and p53 α levels on the DNA-damage response to CIS or DOX in breast cancer cells. Our findings show that $\Delta 40p53$ expression is upregulated by the DNA damaging agent DOX, that it promotes G2-arrest and inhibits apoptosis, changing the canonical p53 α -driven response to this agent. Moreover, a high $\Delta 40p53$:p53 α ratio impairs DOX sensitivity by altering protein interactions following DOX, repressing DOX-mediated changes in gene expression, and ultimately driving cells towards DNA repair and survival.

While a low $\Delta 40p53$:p53 α ratio supported p53's canonical function, leading to an increased proportion of cells in G1 (Fig. 2), accompanied by pro-apoptotic gene expression (Fig. 3E–L), and apoptosis (Fig. 3A, Supplementary Fig. 2H), a high $\Delta 40p53$:p53 α ratio was found to be associated with a reduction of the G1 population (Fig. 2), diminished apoptotic gene expression (Fig. 3M–O), and enhanced cell survival (Fig. 3B, D) in response to DOX and CIS. A high $\Delta 40p53$:p53 α ratio was found to increase the G2 population in response to DOX (Fig. 2H), consistent with $\Delta 40p53$ inducing G2 arrest in response to endoplasmic reticulum stress [33]. Differences in cell cycle regulation may be mediated through *GADD45* (mediates G2), which has been found to be upregulated by $\Delta 40p53$ yet downregulated by p53 α [31].

Altered regulation of apoptotic gene expression and subsequent cell death is likely to be related to the lack of a TAD1 in $\Delta 40p53$. It has been previously described that TAD1-mutated p53 (p53^{L25Q,W26S}), similar to $\Delta 40p53$, is unable to regulate the transcription of *CDKN1A*, *NOXA*, and *PUMA*, and cannot promote cell cycle arrest or apoptosis after acute DNA damage [58, 59], indicating that full-length p53 is required to drive p53's canonical responses (in this case apoptosis) to DNA-damaging agents [60].

Beyond the regulation of specific pro-apoptotic genes, a high $\Delta 40p53$:p53 α was found to block the transcriptional program typically initiated by DOX treatment (Fig. 7A, cluster 1 and 2). While $\Delta 40p53$'s ability to impair transcriptional activation of p53's target genes at baseline and following treatment with DNA-damaging agents has been previously reported in overexpression models [5, 29]; the finding that $\Delta 40p53$ can also impair transcriptional repression is novel, and suggests a more comprehensive deregulation of cell fate following DNA damage. Functional annotations of the RNA-seq results showed that a high $\Delta 40p53$:p53 α ratio was associated with DNA repair, inhibition of apoptosis, proliferation, and worse prognosis (Fig. 7F), supporting altered cell fate in response to DOX in cells with elevated $\Delta 40p53$:p53 α ratios.

Inhibition of transcriptional activation or repression in the presence of elevated $\Delta 40p53$ may be driven by (I) the interaction

of $\Delta 40p53$ and p53 α , with both isoforms shown to co-localise and interact following DNA damage treatment in parental cells (Fig. 5C–F). In this instance, the presence of $\Delta 40p53$ in the oligomers may decrease their stability when bound to DNA (Fig. 5G; Supplementary Fig. 4); therefore, elevated levels of $\Delta 40p53$, and its subsequent incorporation into hetero-tetramers could account for impaired p53 transcriptional function (Fig. 3) and interaction with cofactors. Additionally, by a different mechanism, (II) high levels of $\Delta 40p53$ may contribute to misfolded-p53 aggregates [41] since $\Delta 40p53$ modulates p53 α expression through decreased proteasomal degradation [43, 44] and downregulates *HDM2* [43] (Fig. 4, Fig. 8F, Supplementary Fig. 8D), further altering p53's activities. Alternatively, (III) PTMs of $\Delta 40p53$ and/or electrostatic and hydrophobic interactions between the hetero-tetramer and further downstream signalling, are likely to be significantly impaired, since many proteins interact with TAD1 in a context-dependent fashion following DNA damage [60–64], and hence, as shown by our study, p53-dependent transcription of target genes is compromised when $\Delta 40p53$ is highly expressed (Fig. 3M–P). Finally, (IV) with $\Delta 40p53$ able to bind to some p53 REs [65, 66], $\Delta 40p53$ homo-tetramers may occupy p53 REs and thus, prevent p53 α binding and transactivation/repression. All these hypotheses may account for the repression of the canonical p53 α -mediated transcriptional program (activation and repression) following DOX, when $\Delta 40p53$ is expressed at levels that exceed p53 α , leading to a non-canonical response to DOX-induced genomic stress. It is highly likely that $\Delta 40p53$ exerts these alterations via a combination of the mechanisms described above. Our current model suggests that the primary function of $\Delta 40p53$ in relation to p53 is as a transcription repressor of p53-transcriptional activity in regulating a set of genes involved in the response to DNA damage. In support of this, genes found highly expressed following both $\Delta 40p53$ overexpression and p53 α knockdown such as *MELK*, *NDC80*, *UHRF1*, *TRIP13*, and *RAD51*, have been found to be dysregulated when p53 is deleted or truncated [67–71], suggesting a loss-of-function-like phenotype. However, further analysis is needed to identify how $\Delta 40p53$ represses transcriptional regulation.

The reduced DNA damage when $\Delta 40p53$ was highly expressed may be the result of increased DNA repair, supported by increased expression of *BRCA1* and *RAD51* following DOX (Fig. 6B, C, Fig. 8F, Supplementary Fig. 8I, J). Interestingly, *BRCA1* or *RAD51* did not co-localise with $\Delta 40p53$ and no differences were found in PLA following DOX (Supplementary Fig. 6), suggesting that unlike p53 α this isoform may not efficiently form complexes with these proteins and thus exert less control over DNA repair pathways. It was shown that p53 α 's involvement and regulatory activities in the HR pathway can be mediated via interactions with





Fig. 6 Knockdown of Δ 40p53 increases DNA damage following DOX treatment at early time points. **A** γ H2AX +ve cells after treatment with DOX (3 and 6 h) and normalised by the 0 h in the MCF-7 (-shNT, -sh Δ 40p53, -shp53 α , LeGO and Δ 40p53) and ZR75-1 (-shNT, -sh Δ 40p53, -shp53 α) sublines. γ H2AX (1:50) primary antibody was used. Data shown represent three independent experiments of three technical replicates. **B** BRCA1 and **C** RAD51 expression after treatment with vehicle (water) or DOX (3 h) in the MCF-7 (-shNT, -sh Δ 40p53, -shp53 α , LeGO and Δ 40p53) and ZR75-1 (-shNT, -sh Δ 40p53, -shp53 α) sublines measured by immunofluorescence. BRCA1 (1:100) and RAD51 (1:100) primary antibodies were used. Data shown represent three independent experiments of three technical replicates. Results are shown as the mean \pm SD. Statistical analysis was carried out using two-way ANOVA followed by Sidak's post-test. Results were considered significant at $p < 0.05$; * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$.

RAD51, RAD54 [17], and BRCA1 [72], independently of its transactivation activity [73, 74]. Even though Δ 40p53 maintains the interaction residues with these proteins, it lacks some activation residues of p53 such as the phosphorylation of Ser¹⁵ by upstream kinases, which is required for HR suppression mediated by p53 [75]. We cannot exclude that there might be other factors associated with the lack of co-localisation or PLA results between Δ 40p53 and DNA repair proteins, such as upregulation of other downstream proteins or the formation of misfolded-p53 aggregates as previously mentioned. The analyses shown here are by no means exhaustive and to fully define Δ 40p53 protein interactions further analysis is needed. Nevertheless, these results suggest that in addition to inhibiting the transcriptional repression of p53-target genes (in this case

RAD51), Δ 40p53 may also alter the physical interaction of p53 complexes with signalling proteins.

The deregulated DNA repair in MCF-7- Δ 40p53 cells may cause hyper-recombination, which could lead to genomic instability and the accumulation of DNA mutations. Our data suggest that the Δ 40p53 subline has accumulated more damaged chromosome fragments compared to the LeGO subline, as demonstrated by an increase in the number of micronuclei in this subline (Supplementary Fig. 9). This result supports the hypothesis of deregulated HR when Δ 40p53 is overexpressed. Interestingly, amid the DSB repair genes analysed (*RAD51*, *RAD52*, and *LIG4*), only *RAD51* was upregulated, showing that a high Δ 40p53:p53 α ratio specifically upregulates the HR pathway, contrasting to the Δ 113p53/ Δ 133p53 isoform, which promotes all three DNA DSB repair pathways [76].



Overall, our results indicate that Δ 40p53 is upregulated following DOX, forms complexes with p53 α , stabilises p53, and impairs p53's activation and transactivation of target genes. A high Δ 40p53:p53 α ratio alters the DDR in breast cancer cells, and to some extent, Δ 40p53 behaves similar to TAD1-truncated p53, where p53 loss-of-function is evident in the lack of cell cycle, DNA repair and

apoptosis regulation. Our findings are consistent with the repression of p53-transcriptional activities and impaired protein interactions, leading to prevention of apoptosis after DOX treatment and inhibition of DOX-mediated changes in gene expression. Moreover, inhibiting the expression of Δ 40p53 resulted in enhanced apoptosis, suggesting a potential therapeutic benefit

Fig. 7 Molecular characterisation of the DOX response in MCF-7 and ZR75-1 sublines. Heatmaps of differentially expressed genes (log₂ transformed normalised gene counts) between DOX-treated (24 h) **A** MCF-7-Δ40p53 and MCF-7-LeGO cells; **B** MCF-7-shΔ40p53, MCF-7-shp53α, and MCF-7-shNT cells; and **C** ZR75-1-shΔ40p53, ZR75-1-shp53α, and ZR75-1-shNT cells as determined by RNA-seq analysis. Gene clusters are numbered and indicate genes that follow similar patterns. For comprehensive lists of the differentially expressed genes, see Supplementary Table S2–S6. Venn diagrams show common and specific differentially expressed genes (DOX-treated knockdown and overexpression sublines vs. respective controls) between **D** MCF-7 sublines and **E** Δ40p53 and p53α knockdown sublines (MCF-7 and ZR75-1). For a list of genes represented in each Venn diagram field see Supplementary Table S7–S8). **F** Functional annotations of differentially expressed genes that are linked to DOX response in the MCF-7 sublines. Yellow fields indicate genes that exhibit increased expression and blue fields indicate genes that exhibit decreased expression in DOX-treated sublines with increased levels of Δ40p53 or decreased levels of p53α (i.e. MCF-7-Δ40p53 vs MCF-7-LeGO, MCF-7-shNT vs MCF-7-shΔ40p53, and MCF-7-shNT vs MCF-7-shp53α).

of a co-therapy that combines Δ40p53 silencing with DNA-damaging chemotherapies used in breast cancer treatment. The influence of Δ40p53 levels on other p53-dependent pathways remains to be defined, but most likely Δ40p53 alters p53 function in a context and cell signal-specific fashion.

METHODS

Cell lines

The oestrogen receptor-positive human breast cancer cell lines MCF-7 and ZR75-1, expressing wild-type p53 (WTP53), were kindly provided by Professor Christine Clarke (Westmead Millennium Institute, The University of Sydney, Australia) and Dr Judith Weidenhofer (The University of Newcastle, Australia), respectively. The cell lines were authenticated by the Australian Genome Research Facility as previously described [42]. MCF-7 cells stably overexpressing Δ40p53α via the lentiviral LeGO vector, as well as the empty-vector controls have been previously described [42]. Knockdown sublines (-shNT, -shΔ40p53, and -shp53α) were established by transduction of MCF-7 or ZR75-1 cells with lentiviral vectors containing short hairpin RNAs (shRNA) against Δ40p53, p53, or a non-targeting control (NT) [42] (Sigma-Aldrich, Castle Hill, NSW, Australia). Each of the sublines was maintained in DMEM (Dulbecco modified Eagle's medium) supplemented with 10% foetal bovine serum (FBS), insulin (10 μg/ml), L-glutamine (2 mM) (Life Technologies, Mulgrave, VIC, Australia), and puromycin (1 μg/ml) (Sigma-Aldrich) in humidified 5% CO₂ at 37 °C. Cells were routinely tested for mycoplasma according to the manufacturer's recommendations (MycAlert PLUS, Lonza, Basel, Switzerland).

Cell treatments

Cells were seeded into either 96-well plates at 15,000 cells/well (immunofluorescence and proximity ligation assay) and 5000 cells/well (apoptosis and senescence assays), ultra-low attachment 96-well plates at 4000 cells/well (spheroid assay), 24-well plates at 1 × 10⁵ cells/well (viability assay), or 6-well plates at 5 × 10⁵ cells/well (mRNA, protein analysis, comet assay, and cell cycle analysis). Cells were treated the following day with vehicle (water) or physiologically relevant concentrations of CIS (10 μM) or DOX (1 μM) and/or cycloheximide (CHX; 40 μg/mL) and/or MG132 (10 μM) (Sigma-Aldrich).

Immunofluorescence

Cells were fixed with 3.7% formaldehyde (Sigma-Aldrich) in phosphate-buffered saline (PBS) for 10 min, then permeabilised in 0.1% Triton-X-100 in PBS for 5 min at room temperature and non-specific antibody binding sites were blocked using 3% FBS in PBS for 30 min. After blocking, cells were incubated for 1 h with primary antibodies: mouse-anti-human-γH2AX, 1:50 dilution (Merck, Macquarie Park, NSW, Australia; #05-636); mouse-anti-human-BRCA1, 1:100 dilution (Life Technologies; #MA1-23164); mouse-anti-human-RAD51, 1:100 dilution (Life Technologies; #MA1-23271); mouse-anti-P-p53 (S15), 1:400 dilution (Cell Signaling Technology, Danvers, MA, USA; #9286); rabbit-anti-human-p53 7F5 (which detects the first 50 amino acids of p53), 1:800 dilution (Cell Signaling Technology; #2527); rabbit-anti-human-KJC40 (which detects the Δ40p53 epitope MDDLMLSPDDIEQWFTE with specific PTMs; antibody validation: Supplementary Fig. 1), 1:70 dilution (developed by J.C. Bourdon, The University of Dundee, Scotland), and mouse-anti-human-DO-1 (which detects the sequence ²⁰SDLWKL²⁵ of the TAD1 of p53), 1:100 dilution (Merck; #MABE327). Then, the cells were washed three times with PBS and incubated for 1 h with secondary antibodies: goat-anti-mouse-Alexa-Fluor 594, 1:30 dilution (Life Technologies; #R37121) and/or goat-anti-rabbit-

Alexa 488, 1:500 dilution (Life Technologies; #A11034) or goat-anti-rabbit-Alexa 594, 1:500 dilution (Life Technologies; #A11037). All antibodies were diluted in blocking solution at room temperature. Each well was then stained with DAPI (300 nM in PBS) to detect nuclei. Images were obtained using the Cytation3 cell imager multi-mode reader (BioTek, Winooski, VT, USA) using 10x and 40x objectives. Negative controls were included for each primary and secondary antibody and for DOX (Supplementary Fig. 1). Four images were collected per well maintaining exposure and contrast settings. Images were analysed using the Gen5 software (BioTek) and ImageJ for co-localisation. Images identification was blinded to the investigator.

Proximity ligation assay


To detect protein interactions, proximity ligation assays were performed using Duolink In Situ Red Starter Kit Mouse/Rabbit (Sigma-Aldrich) following the manufacturer's recommendations. Briefly, cells were fixed with 3.7% formaldehyde (Sigma-Aldrich) in PBS for 10 min, then permeabilised in 0.1% Triton-X-100 in PBS for 5 min at room temperature. After blocking, cells were incubated for 1 h at room temperature with primary antibodies (DO-1 and KJC40; 7F5 and BRCA1 or RAD51; KJC40 and BRCA1 or RAD51; details including dilutions of each antibody are described above). Then, cells were incubated for 1 h at 37 °C with the proximity ligation assay probes, followed by ligation of the probes for 30 min at 37 °C and amplification for 100 min at 37 °C. After the final washes, the cells were stained with DAPI. Images were obtained using the Cytation3 cell imager multi-mode reader (BioTek) using 20x and 40x objectives. Negative controls, which lacked the primary antibodies but contained the PLA probes or that contained the primary antibodies but lacked the PLA probes or that contained only one primary antibody and the PLA probes were included. Biological controls were also included: MCF-7-Δ40p53 cells were used as a positive control and MCF-7-shp53α were used as a negative control to assess the Δ40p53 and p53α interaction. Four images were collected per well maintaining exposure and contrast settings. Approximately 40 cells were evaluated per triplicate. Images were analysed using Gen5 software (BioTek) and the relative fluorescence units, as well as the number of puncta per cell, were recorded. Images identification was blinded to the investigator.

Cell cycle analysis

After 24 h treatments, cells were trypsinised and fixed with cold 70% ethanol for 1 h at 4 °C. Fixed cells were washed twice with cold PBS and stained with FxCycle™ PI/RNase Staining Solution for 15 min at room temperature, protected from light. Data were acquired on a FACSCanto™ flow cytometer (BD Biosciences, Macquarie Park, NSW, Australia). Five thousand events were collected for each sample. Data were analysed using Kaluza™ software (Beckman Coulter, Indianapolis, IN, USA). Doublets were removed using forward scatter (FSC) height vs FSC area plots. Cell counts were plotted against PI staining intensity and gates were drawn to delineate G1, S, and G2 cell populations. Cell populations at G1, S, and G2 were normalised to untreated cells within the same phase in order to identify the relative changes.

Apoptosis and viability assays

For MCF-7 cells, IncuCyte Annexin-V red reagent (Essen Bioscience, Ann Arbor, MI, USA) was added to the cells at the time of DOX or CIS treatment at a dilution of 1:200 in PBS. Labelled cells were imaged every 3 h using the IncuCyte Zoom live-cell imaging system (Essen Bioscience). Images were analysed using the IncuCyte Zoom 2016B software. The proportion of Annexin-V positive cells was normalised to the confluence of each image to account for any variability in cell number. Data are shown as the



proportion of Annexin-V positive cells at each time point relative to the proportion at 0 h. For ZR75-1 cells, the Trypan blue exclusion assay and Promega RealTime-Glo™ Annexin V Apoptosis assays were used. For Trypan blue, cells were counted after treatment using the automated cell counter Countess II (Life Technologies). Data are shown as the percentage of viable cells for each time point relative to vehicle-treated cells. For

apoptosis, 100 μl of media containing vehicle, CIS or DOX was mixed with diluted Detection Reagent including Annexin V-SmBIT, Annexin V-LgBIT, and CaCl₂. The Cytation3 cell imager multi-mode reader (BioTek) was used to read the luminescent values every 24 h starting from 0 h. Data are shown as the proportion of Annexin-V luminescence at each time point relative to 0 h time point.

Fig. 8 Gene expression of p53 interactors in the MCF-7 sublines. A–D RNA-seq validation. Gene expression after DOX treatment (24 h) in the MCF-7 (-shNT, -sh Δ 40p53, -shp53 α , LeGO and Δ 40p53) sublines. **A** *MELK*, **B** *NDC80*, **C** *UHRF1* and **D** *TRIP13*. Data shown represent three independent experiments of three technical replicates. Results are shown as the mean \pm SD and were normalised by the relative expression of the vehicle-treated cells. Statistical analyses were carried out using two-way ANOVA followed by Sidak's post-test. Results were considered significant at $p < 0.05$; * $p < 0.05$, ** $p < 0.01$. **E** Interaction between differentially expressed genes (DEGs) and p53 pathway proteins based on STRING data of high confidence (overall interaction score >0.9 ; see Supplementary Table S9 for breakdown of score). Orange – p53 pathway proteins; Blue: DEGs in DOX-treated MCF-7-sh Δ 40p53 vs MCF-7-shNT; Green – DEGs in DOX-treated MCF-7- Δ 40p53 vs MCF-7-LeGO; Yellow – DEGs in DOX-treated MCF-7-sh Δ 40p53 vs MCF-7-shNT and MCF-7- Δ 40p53 vs MCF-7-LeGO. **F** Heatmaps of mRNA levels of p53 interactors: *ATM*, *ATR*, *CHECK2*, *HDM2*, *MAPK1*, *EP300*, *TOPOIIa*, *TOPOIIb*, *BRCA1*, *RAD51*, *RAD52*, *LIG4*, *PARP1*, *APEX1* and *OGG1* after 6 or 24 h of DOX treatment and normalised to vehicle-treated cells in the MCF-7 (-shNT, -sh Δ 40p53, -shp53 α , LeGO and Δ 40p53) sublines (see Supplementary Fig. 7, 8 for comparison between sublines and statistical analyses). Data shown represent three independent experiments of three technical replicates.

Cell spheroids assay

Cells were seeded in ultra-low attachment 96-well plates (Corning, NY, United States), centrifuged for 5 min at 200 \times g and incubated for two days to allow the formation of cell spheroids. Medium containing vehicle or DOX was then added to each well. After four days of treatment, half of the media was replenished with further treatment-containing media and spheroids were incubated for an additional four days, then, half of the media was replenished with complete drug-free media and spheroids were incubated for an additional four days. The spheroids were imaged every second day using the Cytation3 cell imager (BioTek) for spheroid size measurement, relative to their size prior to treatment. Spheroid viability was assessed using the CellTiter-Glo 3D assay (Promega, United States) on the 14th day according to the manufacturers' instructions. Data are shown as the percentage of spheroid viability relative to vehicle-treated spheroids.

Alkaline comet assay

Alkaline comet assays were performed as previously described by Singh et al. [77], with minor modifications. Briefly, 30 μ L of cell suspension was mixed with 70 μ L low-melting point agarose, spread on an agarose pre-coated microscope slide and placed at 4 °C for 10 min to allow solidification. Cells were lysed in a high concentration salt and detergent solution (2.5 M NaCl, 100 mM Na₂EDTA, 10 mM Tris with 1% Triton-X 100%, and 10% DMSO) for 24 h. Slides were removed from the lysis solution and washed three times with PBS. Next, cells were exposed to alkali conditions (300 mM NaOH, 1 mM Na₂EDTA, pH >13 , 15 min, 4 °C). Following DNA unwinding, the slides were subjected to electrophoresis at 1.7 V/cm for 15 min using a Sub-Cell DNA Gel Electrophoresis Apparatus (Bio-Rad, Gladesville, NSW, Australia). Slides were neutralised and stained with GelGreen® (Biotium, Fremont, CA, USA) and mounting media (Agilent Technologies, Mulgrave VIC, Australia). Slide images were captured using a Cytation3 with a 20x objective, and all slides were analysed using the freeware TriTek CometScore. The tail moment was measured (Tail moment = tail length \times % of DNA in the tail) for 100 cells on two slides per biological triplicate. All results were compared to vehicle treatments.

Gene expression

RNA isolation. Total RNA was extracted from all cell lines using TRIzol RNA purification reagent (Life Technologies) following manufacturer's recommendations. The RNA yield was determined by the Qubit RNA BR (broad range) Assay Kit (Life Technologies) on a Qubit 2.0 Fluorometer (Life Technologies), following manufacturer recommendations. RNA integrity was assessed using the Agilent 4200 TapeStation System and the Agilent High Sensitivity (HS) RNA ScreenTape assay (Agilent Technologies). An RNA integrity number (RIN) was given for each sample. Samples with a RIN ≥ 7 were used for RNA-seq described below.

Reverse transcription quantitative polymerase chain reactions (RT-qPCR) 500 ng of total RNA was reverse transcribed into complementary DNA (cDNA) using the High-Capacity Reverse Transcription kit with RNase inhibitor (Life Technologies), as per the manufacturer's instructions. No template RNA and no reverse transcriptase controls were included. PCR efficiency curves were used to select an appropriate cDNA dilution within the linear detection range (around 10 ng/reaction). TaqMan Advanced Master Mix (Life Technologies) and TaqMan Gene Expression assays for p53 target genes (including primers and probes: Supplementary Table S1; Life Technologies), Δ 40p53 (as previously described [38]), *TP53*, and *GAPDH* as an endogenous control were used. Relative expression was calculated using the $2^{-\Delta\Delta C_t}$ method. For *MELK*, *NDC80*, *UHRF1* and *TRIP13*, expression is shown as relative expression. For the other primers, expression is shown as fold-change compared to relative expression of vehicle-treated samples.

RNA-sequencing. RNA libraries were generated using the Illumina stranded mRNA library preparation kit. Pooled libraries were loaded onto a 500/550 High Output Flow Cell (single-end, 75 cycles) and run on a NextSeq 500 system (Illumina, San Diego, CA, USA). FASTQ files were produced by BaseSpace (Illumina) and mapped to Human GRCh37 Assembly using STAR [78]. Differential expression was computed in DESeq2. Genes of ≥ 50 counts, $\log_2(\text{fold change}) \geq |1|$ with a false discovery rate (FDR) adjusted p -value ≤ 0.05 were considered differentially expressed.

Gene Set enrichment analysis. Gene set enrichment analysis (GSEA) was carried out by Enrichr [79] using GO Biological Process 2018. Biological processes were based on 100 most relevant genes (where more than 100 DEGs were searched) and processes with an adjusted p value of <0.05 were deemed significant. Processes with odds ratios >2 or <0.5 were considered as up- or down-regulated processes respectively.

Protein interaction network. Interactions between differentially expressed genes and other p53 and DDR genes were assessed at the protein level using the STRING database [56]. Only interactions of high confidence (interaction score >0.9) were considered.

Protein expression

Sample preparation. Cell pellets were lysed in 1% NP-40 lysis buffer (50 mM Tris-HCl, 150 mM NaCl, 1% NP-40, pH 8.0, 1 \times Mini complete Protease Inhibitor cocktail tablet per 10 ml) and sonicated using the Bioruptor sonicator (Diagenode, Liège, Belgium). Protein concentrations were assessed using a Bradford assay (Bio-Rad) according to the manufacturer's instructions and the absorbance was read on an Implen NanoPhotometer (Implen, München, Germany).

Co-immunoprecipitation. p53 was immunoprecipitated from 500 μ g protein extract (from DOX-treated MCF-7- Δ 40p53 cells) using 1 μ g of anti-p53 (DO-1) and the Dynabeads Protein G Immunoprecipitation Kit (Life Technologies) according to manufacturer's recommendations. Mouse IgG Isotype Control (Life Technologies) was used to estimate non-specific binding of primary antibodies.

Immunoblot assays. Proteins were separated by sulphate dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) as previously described [42]. The membrane was blocked with Casein Blocking Buffer (Millennium Science, Mulgrave VIC, Australia) or Intercept™ PBS Blocking Buffer (LI-COR Biosciences, Lincoln, NE, USA) at room temperature for 1 h. The following primary antibodies were diluted in blocking buffer: CM-1 (pan-p53 polyclonal antibody, which recognises epitopes located between amino acids 1 and 393), 1 μ g/ml; KJC40, 2.5 μ g/ml (The University of Dundee, Scotland); DO-1, 1 μ g/ml (Merck); 7F5, 1 μ g/ml (Cell Signaling Technology); mouse GAPDH, 1 μ g/ml (Calbiochem, San Diego, CA, USA; #CB1001); rabbit GAPDH, 1 μ g/ml (Abcam, Melbourne, VIC, Australia; #ab128915), and added to the membrane overnight (4 °C, rocking). Diluted secondary antibodies (1–5 μ g/ml; LI-COR Biosciences; #926-32210 and #926-68023) in blocking buffer were added and allowed to bind on a rocker for at least 1 h at room temperature. Bands were visualised and quantitated using an Odyssey CLx fluorescent imager (LI-COR Biosciences) relative to the loading control (GAPDH).

In silico analysis

The stability of p53 α and Δ 40p53 hetero-complexes with DNA was evaluated by molecular docking. Briefly, the structures of the p53 complexes were generated by homology modelling using the target sequence UniProtKB P04637, residues 94–356 and template structures:

PDB ID 4MZR (Chains A–D, residues 94–358), PDB ID 3EXJ (Chain A, residues 98–291), PDB ID 4IBU (Chains A, B, residues 94–293), and PDB ID 1OLG (Chain A, residues 319–360). Discovery Studio v.18.1 (Biovia) was used, to create the multiple sequence alignments, homology models, loop modelling of residues 14–60 using PDB ID 2K8F (Chain, residues 14–60), tetrameric complexes, and energy minimisations. Combinations of p53 and $\Delta 40p53$ subunits were docked into tetramer complexes with DNA (ZDOCK), using PDB ID 4MZR as the template. Each tetramer/DNA complex was then energy minimised (CHARMM) with the resultant potential energy (kcal/mol) reported.

Statistical analysis

Unpaired student *t*-tests were performed for two comparisons and one-way ANOVA or two-way ANOVA for multiple comparisons, corrected for multiple comparisons using the Dunnett's test, Tukey's test (one-way), or Sidak's test (two-way). All results are the mean of three independent experiments (*n* of technical replicates are indicated in the figure legends), and error bars represent the standard deviation (SD). All statistical analyses were performed using GraphPad Prism v. 6.0 (GraphPad Software, La Jolla, CA, USA). An adjusted *p*-value of <0.05 was considered statistically significant.

DATA AVAILABILITY

The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.

REFERENCES

- Forbes SA, Bindal N, Bamford S, Cole C, Kok CY, Beare D, et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. *Nucleic Acids Res.* 2011;39:D945–50.
- Olivier M, Hollstein M, Hainaut P. TP53 mutations in human cancers: origins, consequences, and clinical use. *Cold Spring Harb Perspect Biol.* 2010;2:a001008.
- Cancer Genome Atlas N. Comprehensive molecular portraits of human breast tumours. *Nature* 2012;490:61–70.
- Oakman C, Pestrin M, Cantisani E, Licitra S, DeStefanis M, Biganzoli L, et al. Adjuvant chemotherapy—the dark side of clinical trials. Have we learnt more? *Breast.* 2009;18:S18–24.
- Ghosh A, Stewart D, Matlashewski G. Regulation of human p53 activity and cell localization by alternative splicing. *Mol Cell Biol.* 2004;24:7987–97.
- Walerych D, Napoli M, Collavin L, Del, Sal G. The rebel angel: mutant p53 as the driving oncogene in breast cancer. *Carcinogenesis.* 2012;33:2007–17.
- Vousden KH, Lu X. Live or let die: the cell's response to p53. *Nat Rev Cancer.* 2002;2:594–604.
- Kubbutat MHG, Jones SN, Vousden KH. Regulation of p53 stability by Mdm2. *Nature* 1997;387:299–303.
- Gasco M, Shami S, Crook T. The p53 pathway in breast cancer. *Breast Cancer Res.* 2002;4:70–6.
- Al-Khalaf HH, Abousekhra A. p16 Controls p53 Protein Expression Through miR-dependent Destabilization of MDM2. *Mol Cancer Res.* 2018;16:1299–308.
- Williams AB, Schumacher B. p53 in the DNA-Damage-Repair Process. *Cold Spring Harb Perspect Med.* 2016;6:5.
- Gatz SA, Wiesmüller L. p53 in recombination and repair. *Cell Death Differ.* 2006;13:1003–16.
- Helton ES, Chen X. p53 modulation of the DNA damage response. *J Cell Biochem.* 2007;100:883–96.
- Meek DW. Tumour suppression by p53: a role for the DNA damage response? *Nat Rev Cancer.* 2009;9:714–23.
- Kumari SR, Mendoza-Alvarez H, Alvarez-Gonzalez R. Functional interactions of p53 with poly(ADP-ribose) polymerase (PARP) during apoptosis following DNA damage: covalent poly(ADP-ribosylation) of p53 by exogenous PARP and non-covalent binding of p53 to the Mr() 85,000 proteolytic fragment. *Cancer Res.* 1998;58:5075–8.
- Buchhop S, Gibson MK, Wang XW, Wagner P, Stürzbecher HW, Harris CC. Interaction of p53 with the human Rad51 protein. *Nucleic Acids Res.* 1997;25:3868–74.
- Linke SP, Sengupta S, Khabie N, Jeffries BA, Buchhop S, Miska S, et al. p53 interacts with hRAD51 and hRAD54, and directly modulates homologous recombination. *Cancer Res.* 2003;63:2596–605.
- Romanova LY, Willers H, Blagosklonny MV, Powell SN. The interaction of p53 with replication protein A mediates suppression of homologous recombination. *Oncogene.* 2004;23:9025–33.
- Zhang H, Somasundaram K, Peng Y, Tian H, Zhang H, Bi D, et al. BRCA1 physically associates with p53 and stimulates its transcriptional activity. *Oncogene.* 1998;16:1713–21.
- Marmorstein LY, Ouchi T, Aaronson SA. The BRCA2 gene product functionally interacts with p53 and RAD51. *Proc Natl Acad Sci.* 1998;95:13869–74.
- Wang XW, Tseng A, Ellis NA, Spillare EA, Linke SP, Robles AI, et al. Functional interaction of p53 and BLM DNA helicase in apoptosis. *J Biol Chem.* 2001;276:32948–55.
- Blander G, Kipnis J, Leal JF, Yu CE, Schellenberg GD, Oren M. Physical and functional interaction between p53 and the Werner's syndrome protein. *J Biol Chem.* 1999;274:29463–9.
- Mekeel KL, Tang W, Kachnic LA, Luo CM, DeFrank JS, Powell SN. Inactivation of p53 results in high rates of homologous recombination. *Oncogene.* 1997;14:1847–57.
- Akyüz N, Boehden GS, Süsse S, Rimek A, Preuss U, Scheidtmann KH, et al. DNA substrate dependence of p53-mediated regulation of double-strand break repair. *Mol Cell Biol.* 2002;22:6306–17.
- Keimling M, Wiesmüller L. DNA double-strand break repair activities in mammary epithelial cells—influence of endogenous p53 variants. *Carcinogenesis.* 2009;30:1260–8.
- Bourdon JC, Fernandes K, Murray-Zmijewski F, Liu G, Diot A, Xirodimas DP, et al. p53 isoforms can regulate p53 transcriptional activity. *Genes Dev.* 2005;19:2122–37.
- Marcel V, Perrier S, Aoubala M, Ageorges S, Groves MJ, Diot A, et al. Delta160p53 is a novel N-terminal p53 isoform encoded by Delta133p53 transcript. *FEBS Lett.* 2010;584:4463–8.
- Steffens Reinhardt L, Zhang X, Wawruszak A, Groen K, De Iulius GN, Avery-Kiejda KA. Good Cop, Bad Cop: Defining the Roles of Delta40p53 in Cancer and Aging. *Cancers (Basel).* 2020;12:1659.
- Avery-Kiejda KA, Zhang XD, Adams LJ, Scott RJ, Wojtesek B, Lane DP, et al. Small molecular weight variants of p53 are expressed in human melanoma cells and are induced by the DNA-damaging agent cisplatin. *Clin Cancer Res.* 2008;14:1659–68.
- Yin Y, Stephen CW, Luciani MG, Fahraeus R. p53 Stability and activity is regulated by Mdm2-mediated induction of alternative p53 translation products. *Nat Cell Biol.* 2002;4:462–7.
- Powell DJ, Hrstka R, Candeias M, Bourougaa K, Wojtesek B, Fahraeus R. Stress-dependent changes in the properties of p53 complexes by the alternative translation product p53/47. *Cell cycle (Georget, Tex)* 2008;7:950–9.
- Fujita K, Mondal AM, Horikawa I, Nguyen GH, Kumamoto K, Sohn JJ, et al. p53 isoforms Delta133p53 and p53beta are endogenous regulators of replicative cellular senescence. *Nat Cell Biol.* 2009;11:1135–42.
- Bourougaa K, Naski N, Boularan C, Mlynarczyk C, Candeias MM, Marullo S, et al. Endoplasmic reticulum stress induces G2 cell-cycle arrest via mRNA translation of the p53 isoform p53/47. *Mol Cell.* 2010;38:78–88.
- Davidson W, Kari C, Ren Q, Daroczi B, Dicker A, Rodeck U. Differential regulation of p53 function by the N-terminal DeltaNp53 and Delta113p53 isoforms in zebrafish embryos. *BMC Developmental Biol.* 2010;10:102.
- Bernard H, Garmy-Susini B, Ainaoui N, Van Den Bergh L, Peurichard A, Javerzat S, et al. The p53 isoform, [Delta]133p53[alpha], stimulates angiogenesis and tumour progression. *Oncogene.* 2012;32:2150–60.
- Slatter TL, Hung N, Campbell H, Rubio C, Mehta R, Renshaw P, et al. Hyperproliferation, cancer, and inflammation in mice expressing a $\Delta 133p53$ -like isoform. *Blood.* 2011;117:5166–77.
- Courtois S, Verhaegh G, North S, Luciani MG, Lassus P, Hibner U, et al. DeltaN-p53, a natural isoform of p53 lacking the first transactivation domain, counteracts growth suppression by wild-type p53. *Oncogene.* 2002;21:6722–8.
- Avery-Kiejda KA, Morten B, Wong-Brown MW, Mathe A, Scott RJ. The relative mRNA expression of p53 isoforms in breast cancer is associated with clinical features and outcome. *Carcinogenesis.* 2014;35:586–96.
- Morten BC, Wong-Brown MW, Scott RJ, Avery-Kiejda KA. The presence of the intron 3 16 bp duplication polymorphism of p53 (rs17878362) in breast cancer is associated with a low Delta40p53:p53 ratio and better outcome. *Carcinogenesis.* 2016;37:81–6.
- Ungewitter E, Scrabble H. Delta40p53 controls the switch from pluripotency to differentiation by regulating IGF signaling in ESCs. *Genes Dev.* 2010;24:2408–19.
- Melo Dos Santos N, de Oliveira GAP, Ramos Rocha M, Pedrote MM, Diniz da Silva Ferretti G, Pereira Rangel L, et al. Loss of the p53 transactivation domain results in high amyloid aggregation of the Delta40p53 isoform in endometrial carcinoma cells. *J Biol Chem.* 2019;294:9430–9.
- Zhang X, Groen K, Morten BC, Steffens Reinhardt L, Campbell HG, Braithwaite AW, et al. The effect of p53 and its N-terminally truncated isoform, $\Delta 40p53$, on breast cancer migration and invasion. *Mol Oncol.* 2021;16:447–65.
- Hafsi H, Santos-Silva D, Courtois-Cox S, Hainaut P. Effects of Delta40p53, an isoform of p53 lacking the N-terminus, on transactivation capacity of the tumor suppressor protein p53. *BMC Cancer.* 2013;13:134.
- Ota A, Nakao H, Sawada Y, Karnan S, Wahiduzzaman M, Inoue T, et al. Delta40-p53alpha suppresses tumor cell proliferation and induces cellular senescence in hepatocellular carcinoma cells. *J Cell Sci.* 2017;130:614–25.

45. Graupner V, Schulze-Osthoff K, Essmann F, Janicke RU. Functional characterization of p53beta and p53gamma, two isoforms of the tumor suppressor p53. *Cell cycle (Georget, Tex)* 2009;8:1238–48.
46. Yang F, Teves SS, Kemp CJ, Henikoff S. Doxorubicin, DNA torsion, and chromatin dynamics. *Biochimica et Biophysica Acta (BBA) - Rev Cancer*. 2014;1845:84–9.
47. Xu J, Shi Q, Xu W, Zhou Q, Shi R, Ma Y, et al. Metabolic enzyme PDK3 forms a positive feedback loop with transcription factor HSF1 to drive chemoresistance. *Theranostics*. 2019;9:2999–3013.
48. Zhang Y, Lei Y, Xu J, Hua J, Zhang B, Liu J, et al. Role of Damage DNA-Binding Protein 1 in Pancreatic Cancer Progression and Chemoresistance. *Cancers (Basel)*. 2019;11:1998.
49. Naghavi L, Schwalbe M, Ghanem A, Naumann M. Deubiquitinylase USP47 Promotes RelA Phosphorylation and Survival in Gastric Cancer Cells. *Biomedicines*. 2018;6:62.
50. Mahadevappa R, Neves H, Yuen SM, Bai Y, McCrudden CM, Yuen HF, et al. The prognostic significance of Cdc6 and Cdt1 in breast cancer. *Sci Rep*. 2017;7:985.
51. Shuai W, Wu J, Chen S, Liu R, Ye Z, Kuang C, et al. SUV39H2 promotes colorectal cancer proliferation and metastasis via tri-methylation of the SLIT1 promoter. *Cancer Lett*. 2018;422:56–69.
52. Wang D, Wang S, Chen L, He D, Han S, Huang B, et al. The correlation of PTPN4 expression with prognosis in breast cancer. *Int J Clin Exp Pathol*. 2018;11:4845–53.
53. Zhang J, Zhang J, Xu S, Zhang X, Wang P, Wu H, et al. Hypoxia-Induced TPM2 Methylation is Associated with Chemoresistance and Poor Prognosis in Breast Cancer. *Cell Physiol Biochem*. 2018;45:692–705.
54. Zhang Y, Xu W, Ni P, Li A, Zhou J, Xu S. MiR-99a and MiR-491 Regulate Cisplatin Resistance in Human Gastric Cancer Cells by Targeting CAPNS1. *Int J Biol Sci*. 2016;12:1437–47.
55. Mandinova A, Lee SW. The p53 pathway as a target in cancer therapeutics: obstacles and promise. *Sci Transl Med*. 2011;3:64rv1–rv1.
56. Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J, et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. *Nucleic Acids Res*. 2019;47:D607–D13.
57. Vieler M, Sanyal S. p53 Isoforms and Their Implications in Cancer. *Cancers (Basel)*. 2018;10:288.
58. Johnson TM, Hammond EM, Giaccia A, Attardi LD. The p53Q5 transactivation-deficient mutant shows stress-specific apoptotic activity and induces embryonic lethality. *Nat Genet*. 2005;37:145–52.
59. Brady Colleen A, Jiang D, Mello Stephano S, Johnson Thomas M, Jarvis Lesley A, Kozak, Margaret M, et al. Distinct p53 Transcriptional Programs Dictate Acute DNA-Damage Responses and Tumor Suppression. *Cell* 2011;145:571–83.
60. Raj N, Attardi LD. The Transactivation Domains of the p53 Protein. *Cold Spring Harb Perspect Med*. 2017;7:a026047.
61. Laptenko O, Prives C. Transcriptional regulation by p53: one protein, many possibilities. *Cell Death Differ*. 2006;13:951–61.
62. Beckerman R, Prives C. Transcriptional regulation by p53. *Cold Spring Harb Perspect Biol*. 2010;2:a000935.
63. Sullivan KD, Galbraith MD, Andrysk Z, Espinosa JM. Mechanisms of transcriptional regulation by p53. *Cell Death Differ*. 2018;25:133–43.
64. Coutts AS, La, Thangue N. The p53 response during DNA damage: impact of transcriptional cofactors. *Biochem Soc Symp*. 2006;73:181–9.
65. Hafsi H, Santos-Silva D, Courtois-Cox S, Hainaut P. Effects of $\Delta 40p53$, an isoform of p53 lacking the N-terminus, on transactivation capacity of the tumor suppressor protein p53. *BMC Cancer*. 2013;13:134.
66. Levandowski CB, Jones T, Gruca M, Ramamoorthy S, Dowell RD, Taatjes DJ. The $\Delta 40p53$ isoform inhibits p53-dependent eRNA transcription and enables regulation by signal-specific transcription factors during p53 activation. *PLoS Biol*. 2021;19:e3001364.
67. Bollu LR, Shepherd J, Zhao D, Ma Y, Tahaney W, Speers C, et al. Mutant P53 induces MELK expression by release of wild-type P53-dependent suppression of FOXM1. *Npj Breast Cancer*. 2020;6:2.
68. Li J, Xu X, Peng X. NDC80 Enhances Cisplatin-resistance in Triple-negative Breast Cancer. *Arch Med Res*. 2022;53:378–87.
69. Alhosin M, Abusnina A, Achour M, Sharif T, Muller C, Peluso J, et al. Induction of apoptosis by thymoquinone in lymphoblastic leukemia Jurkat cells is mediated by a p73-dependent pathway which targets the epigenetic integrator UHRF1. *Biochem Pharm*. 2010;79:1251–60.
70. Arima Y, Hirota T, Bronner C, Mousli M, Fujiwara T, Niwa S, et al. Down-regulation of nuclear protein ICBP90 by p53/p21Cip1/WAF1-dependent DNA-damage checkpoint signals contributes to cell cycle arrest at G1/S transition. *Genes Cells*. 2004;9:131–42.
71. Arias-Lopez C, Lazaro-Trueba I, Kerr P, Lord CJ, Dexter T, Iravani M, et al. p53 modulates homologous recombination by transcriptional regulation of the RAD51 gene. *EMBO Rep*. 2006;7:219–24.
72. Dong C, Zhang F, Luo Y, Wang H, Zhao X, Guo G, et al. p53 suppresses hyper-recombination by modulating BRCA1 function. *DNA Repair (Amst)*. 2015;33:60–9.
73. Dudenhöffer C, Kurth M, Janus F, Deppert W, Wiesmüller L. Dissociation of the recombination control and the sequence-specific transactivation function of P53. *Oncogene*. 1999;18:5773–84.
74. Willers H, McCarthy EE, Wu B, Wunsch H, Tang W, Taghian DG, et al. Dissociation of p53-mediated suppression of homologous recombination from G1/S cell cycle checkpoint control. *Oncogene*. 2000;19:632–9.
75. Sirbu BM, Lachmayer SJ, Wülfing V, Marten LM, Clarkson KE, Lee LW, et al. ATR-p53 restricts homologous recombination in response to replicative stress but does not limit DNA interstrand crosslink repair in lung cancer cells. *PLoS One*. 2011;6:e23053.
76. Gong H, Zhang Y, Jiang K, Ye S, Chen S, Zhang Q, et al. p73 coordinates with $\Delta 133p53$ to promote DNA double-strand break repair. *Cell Death Differ*. 2018;25:1063–79.
77. Singh NP, McCoy MT, Tice RR, Schneider EL. A simple technique for quantitation of low levels of DNA damage in individual cells. *Exp Cell Res*. 1988;175:184–91.
78. Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast universal RNA-seq aligner. *Bioinformatics*. 2013;29:15–21.
79. Kuleshov MV, Jones MR, Rouillard AD, Fernandez NF, Duan Q, Wang Z, et al. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. *Nucleic Acids Res*. 2016;44:W90–7.

ACKNOWLEDGEMENTS

The authors would like to thank Professor Christine Clarke (Westmead Millennium Institute, The University of Sydney, Australia) and Dr Judith Weidenhofer (The University of Newcastle, Australia) who provided the human breast cancer cell lines MCF-7 and ZR75-1 used in this study, and Dr Heather Lee who reviewed the final draft of the manuscript. The authors would like to express their gratitude for the financial support of The Hunter Medical Research Institute and The University of Newcastle. Luiza Steffens Reinhardt is supported by a University Postgraduate Award. XZ is supported by Sanyal Postgraduate Award and a Hunter Cancer Research Alliance PhD Scholarship. KAAK is supported by the Cancer Institute NSW (Career Development Fellowship; CDF181205).

AUTHOR CONTRIBUTIONS

LSR, XZ, KG, BCM and KAAK conceived and planned the experiments. LSR, XZ, KG and BCM acquired the data. LSR, XZ, KG, BCM and KAAK analysed and interpreted the data. GNDI developed the in silico simulations and interpreted the data. AWB generated the MCF-7- $\Delta 40p53$ subline. LSR wrote the original draft. LSR, XZ, KG and KAAK wrote and edited the manuscript. BCM, AWB and JCB provided insights into data interpretation and feedback to the final draft of the manuscript. KAAK provided student supervision, project direction and obtained funding. All authors reviewed the final manuscript.

ETHICS APPROVAL

No animals and/or humans requiring approval by an ethics committee were engaged. The study concept was in accordance with the Declaration of Helsinki.

COMPETING INTERESTS

The authors declare no competing interests.

ADDITIONAL INFORMATION

Supplementary information The online version contains supplementary material available at <https://doi.org/10.1038/s41419-022-05349-9>.

Correspondence and requests for materials should be addressed to Kelly A. Avery-Kiejda.

Reprints and permission information is available at <http://www.nature.com/reprints>

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2022